Target intelligence / Profile preview

N-acetyltransferase pseudogene (NATP)

Target: NATP
Molecular classification: Other (pseudogene)

Overview

The N-acetyltransferase pseudogene (NATP, NATP1) is located at human chromosome 8p21.3 and is classified as a pseudogene, meaning it shares sequence similarity with the active N-acetyltransferase 1 (NAT1) and N-acetyltransferase 2 (NAT2) genes but does not encode a functional protein product[2][3][4]. It lacks evidence of protein expression or enzymatic activity and is not implicated in disease or considered a therapeutic or diagnostic target[2][3][4]. NATP is distinct from the functional NAT1 and NAT2 arylamine N-acetyltransferase enzymes involved in xenobiotic and drug metabolism[1][2][5]. This entry is not a therapeutic target, and the name may be confused with the functionally important NAT1 or NAT2 acetyltransferases.

Other names: NATP1N-acetyltransferase pseudogene

Beyond the preview

Go deeper on N-acetyltransferase pseudogene (NATP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-acetyltransferase pseudogene (NATP).

Explore the full profile